Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,

Stefano Iacovelli, Maria Rosaria Ricciardi, PhD, Paola Bergamo, Cinzia Rinaldo, PhD, Roberto Licchetta, Antonella Vitale, Anna Testi, MD, Maria Teresa Petrucci, MD, Marina Konopleva, MD, PhD, Michele Milella, MD, Robin Foà, Agostino Tafuri

Blood (2011) 118 (21): 3581.

https://doi.org/10.1182/blood.V118.21.3581.3581

Published: 2011

Journal Articles

Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia

Stefano Iacovelli, Maria Rosaria Ricciardi, PhD, Andrea Miele, Paola Bergamo, Roberto Licchetta, Antonella Vitale, MD, Anna Testi, MD, Maria Teresa Petrucci, MD, Michele Milella, MD, Robin Foà, MD, Agostino Tafuri, MD

Blood (2010) 116 (21): 3228.

https://doi.org/10.1182/blood.V116.21.3228.3228

Published: 2010

Journal Articles

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Maria Rosaria Ricciardi, PhD, Roberto Licchetta, Paola Bergamo, Stefano Iacovelli, Andrea Miele, Maria Teresa Petrucci, MD, Michele Milella, MD, Claudio Pisano, PhD, Agostino Tafuri, MD

Blood (2010) 116 (21): 4946.

https://doi.org/10.1182/blood.V116.21.4946.4946

Published: 2010

Journal Articles

Preclinical Approach to Sensitize Multiple Myeloma Cells: Combination of the MEK Inhibitor PD0325901 with ABT-737 or Mevinolin.

Maria Rosaria Ricciardi, Elisabetta Calabrese, Michele Milella, Paola Bergamo, Samantha Decandia, Cinzia De Benedictis, Robin Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2009) 114 (22): 1842.

https://doi.org/10.1182/blood.V114.22.1842.1842

Published: 2009

Journal Articles

Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.

Maria Rosaria Ricciardi, Samantha Decandia, Paola Bergamo, Cinzia De Benedictis, Antonella Vitale, Anna Maria Testi, Joanna Fei, Maria Teresa Petrucci, Michele Milella, Robin Foà, Agostino Tafuri

Blood (2009) 114 (22): 985.

https://doi.org/10.1182/blood.V114.22.985.985

Published: 2009

Journal Articles

Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.

Marina Konopleva, MD, PhD, Michele Milella, MD, Julie C Watts, PhD, Maria Rosaria Ricciardi, PhD, Borys Korchin, PhD, Twee Tsao, PhD, Paola Bergamo, MS, Duncan H. Mak, PhD, Samantha Decandia, PhD, James McCubrey, PhD, Agostino Tafuri, MD, Michael Andreeff, MD, PhD

Blood (2009) 114 (22): 2757.

https://doi.org/10.1182/blood.V114.22.2757.2757

Published: 2009

Journal Articles

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Maria Rosaria Ricciardi, PhD, Twee Tsao, PhD, Stephen Lee Abrams, PhD, Paola Bergamo, MS, Linda S Steelman, BS., MS, Samantha Decandia, PhD, Lara Felicioni, PhD, Ludovica Ciuffreda, PhD, Cristina Di Sanza, PhD, Antonio Marchetti, MD, PhD, Francesco Cognetti, MD, James McCubrey, PhD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2009) 114 (22): 594.

https://doi.org/10.1182/blood.V114.22.594.594

Published: 2009

Journal Articles

BCL-2/BCL-XL Inhibition in Smoldering Multiple Myeloma CD138+ Cells: Functional Effects and Protein Expression Levels

Francesco Libotte, Maria Rosaria Ricciardi, Elisabetta Calabrese, Cinzia De Benedictis, Sara Santinelli, Paola Bergamo, Samantha Decandia, Anna Levi, Ali Fathi Mohamad, Vincenzo Federico, Michele Milella, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2008) 112 (11): 5159.

https://doi.org/10.1182/blood.V112.11.5159.5159

Published: 2008

Journal Articles

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways

Maria Rosaria Ricciardi, Michele Milella, Francesco Libotte, Elisabetta Calabrese, Paola Bergamo, Sara Santinelli, Samantha Decandia, Cinzia De Benedictis, Anna Levi, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2008) 112 (11): 5161.

https://doi.org/10.1182/blood.V112.11.5161.5161

Published: 2008

Journal Articles

Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)

Maria Rosaria Ricciardi, PhD, Samantha Decandia, Sara Santinelli, Chiara Gregorj, Fabiana De Cave, Maria Cristina Scerpa, PhD, Paola Bergamo, MS, Francesco Libotte, Cinzia De Benedictis, Antonella Vitale, Maria Teresa Petrucci, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Michele Milella, Robert Foa, Agostino Tafuri

Blood (2008) 112 (11): 5034.

https://doi.org/10.1182/blood.V112.11.5034.5034

Published: 2008

Journal Articles

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Michele Milella, MD, Maria Rosaria Ricciardi, Paola Bergamo, MS, Maria Cristina Scerpa, PhD, Jacopo Gervasoni, MS, Maria Teresa Petrucci, MD, Sabina Chiaretti, MD, Simona Tavolaro, MS, Ludovica Ciuffreda, PhD, Samantha Decandia, Francesco Libotte, Stephen Lee Abrams, Linda S Steelman, BS., MS, Marina Konopleva, MD, PhD, Francesco Cognetti, MD, Robert Foa, Michael Andreeff, MD, PhD, James McCubrey, PhD, Agostino Tafuri

Blood (2008) 112 (11): 860.

https://doi.org/10.1182/blood.V112.11.860.860

Published: 2008

Journal Articles

The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.

Maria Rosaria Ricciardi, PhD, Chiara Gregorj, PhD, Fabiana De Cave, MS, Paola Bergamo, Samantha Decandia, MS, Sara Santinelli, Antonella Vitale, MD, Maria Teresa Petrucci, MD, Michele Milella, MD, Robert Foa, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 155.

https://doi.org/10.1182/blood.V110.11.155.155

Published: 2007

Journal Articles

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Maria Rosaria Ricciardi, PhD, Elisabetta Calabrese, MD, Fabiana De Cave, PhD, Sara Santinelli, Paola Bergamo, Samantha Decandia, PhD, Chiara Gregorj, PhD, Vincenzo Federico, MD, Michele Milella, MD, Robert Foa, MD, Agostino Tafuri, MD, Maria Teresa Petrucci, MD

Blood (2007) 110 (11): 4782.

https://doi.org/10.1182/blood.V110.11.4782.4782

Published: 2007

Journal Articles

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

Michele Milella, MD, Sabina Chiaretti, MD, PhD, Maria R. Ricciardi, PhD, Simona Tavolaro, BSc, Ludovica Ciuffreda, PhD, Barbara Benassi, PhD, Alfonso Bellacosa, MD, PhD, Gianfranco Peluso, PhD, Paola Bergamo, MS, James A. McCubrey, PhD, Francesco Cognetti, MD, Gabriella Zupi, PhD, Robert Foà, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 3470.

https://doi.org/10.1182/blood.V110.11.3470.3470

Published: 2007

Journal Articles

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Blood (2007) 109 (12): 5473–5476.

https://doi.org/10.1182/blood-2006-05-021071

Published: 2007

Includes: Supplemental data

Journal Articles

Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.

James A. McCubrey, PhD, Steven L. Abrams, BS, Linda S. Steelman, MS, Ellis W.T. Wong, BS, William H. Chappell, MS, Jorg Basecke, MD, Franca Stivala, MD, Massimo Libra, MD, PhD, Michele Milella, MD, Agostino Tafuri, MD, Jacob Troppmair, PhD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Camilla Evangelisti, BS, Alberto M. Martelli, MD, PhD

Blood (2006) 108 (11): 1116.

https://doi.org/10.1182/blood.V108.11.1116.1116

Published: 2006

Journal Articles

Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.

Michele Milella, MD, Maria Rosaria Ricciardi, PhD, Chiara Gregorj, PhD, Fabiana De Cave, PhD, Steven L. Abrams, BS, Linda S. Steelman, MS, Sabina Chiaretti, PhD, Marina Konopleva, MD, PhD, Maria Teresa Petrucci, MD, Francesco Cognetti, MD, Robert Foa, MD, PhD, Michael Andreeff, MD, PhD, James McCubrey, PhD, Agostino Tafuri, MD

Blood (2006) 108 (11): 254.

https://doi.org/10.1182/blood.V108.11.254.254

Published: 2006

Journal Articles

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Michele Milella, Marina Konopleva, Cristina M. Precupanu, Yoko Tabe, Maria Rosaria Ricciardi, Chiara Gregorj, Steven J. Collins, Bing Z. Carter, Carmen D'Angelo, Maria Teresa Petrucci, Robin Foà, Francesco Cognetti, Agostino Tafuri, Michael Andreeff

Blood (2006) 109 (5): 2121–2129.

https://doi.org/10.1182/blood-2006-05-024679

Published: 2006

Journal Articles

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Maria R. Ricciardi, PhD, Maria C. Scerpa, PhD, Ludovica Ciuffreda, PhD, Sabina Chiaretti, MD, PhD, Simona Tavolaro, PhD, Jacopo Gervasoni, Fabiana De Cave, PhD, Chiara Gregorj, PhD, Maria T. Petrucci, MD, Francesco Cognetti, MD, Michael Andreeff, MD, PhD, Gabriella Zupi, MD, Robin Foà, MD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2005) 106 (11): 3370.

https://doi.org/10.1182/blood.V106.11.3370.3370

Published: 2005

Journal Articles

Role of Extracellular Signal-Regulated Kinase-1/2 (ERK) on Complete Remission Achievement of Primary Adult Acute Lymphoblastic Leukemia Patients Enrolled in the GIMEMA Protocol LAL 2000: In Vitro Activity of the MEK Inhibithor PD98059.

Blood (2005) 106 (11): 853.

https://doi.org/10.1182/blood.V106.11.853.853

Published: 2005

NARROW

Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,

Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia

Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells

Preclinical Approach to Sensitize Multiple Myeloma Cells: Combination of the MEK Inhibitor PD0325901 with ABT-737 or Mevinolin.

Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.

Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

BCL-2/BCL-XL Inhibition in Smoldering Multiple Myeloma CD138+ Cells: Functional Effects and Protein Expression Levels

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways

Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.

Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Role of Extracellular Signal-Regulated Kinase-1/2 (ERK) on Complete Remission Achievement of Primary Adult Acute Lymphoblastic Leukemia Patients Enrolled in the GIMEMA Protocol LAL 2000: In Vitro Activity of the MEK Inhibithor PD98059.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only